Avinger Inc.
| NASDAQ: AVGR |
| Healthcare / Medical Devices & Instruments / USA |
| 1.55 | +0.0400 | +2.65% | Vol 63.03K | 1Y Perf 32.46% |
| Jun 28th, 2022 16:00 DELAYED |
| BID | 1.54 | ASK | 1.70 | ||
| Open | 1.52 | Previous Close | 1.51 | ||
| Pre-Market | - | After-Market | 1.60 | ||
| - - | 0.05 3.23% |
| Target Price | 7.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 383.87 | Finscreener Ranking | ★★★★ 52.49 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★+ 48.59 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★+ 43.27 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.47 | Earnings Rating | Neutral | |
| Market Cap | 8.81M | Earnings Date | 9th Aug 2022 | |
| Alpha | -0.06 | Standard Deviation | 0.44 | |
| Beta | 1.70 |
Today's Price Range 1.521.62 | 52W Range 1.4229.20 | 5 Year PE Ratio Range -0.6000-0.1000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.67% | ||
| 1 Month | -25.98% | ||
| 3 Months | -53.96% | ||
| 6 Months | 208.16% | ||
| 1 Year | 32.46% | ||
| 3 Years | -50.17% | ||
| 5 Years | -99.14% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -3 546.54 | |||
ROE last 12 Months | -181.77 | |||
ROA (5Y Avg) | -36.14 | |||
ROA last 12 Months | -75.29 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -79.16 | |||
Return on invested Capital Q | -42.83 | |||
Return on invested Capital Y | -21.55 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 6.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.30 | ||||
| 0.89 | ||||
| 0.91 | ||||
| - | ||||
| -0.50 | ||||
| -3.56 | ||||
| 0.89 | ||||
| 1.80 | ||||
| 4.75M | ||||
| Forward PE | -0.44 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.60 | ||||
| 4.70 | ||||
| 0.59 | ||||
| 1.53 | ||||
| -9.30 | ||||
| Leverage Ratio | 2.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 32.30 | ||||
| -167.10 | ||||
| -161.70 | ||||
| -295.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.46M | ||||
| 1.67 | ||||
| 5.75 | ||||
| -6.48 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -1.21 | -2.33 | -92.56 |
| Q04 2021 | -1.26 | -1.26 | 0.00 |
| Q03 2021 | -1.40 | -1.20 | 14.29 |
| Q02 2021 | -0.80 | -0.80 | 0.00 |
| Q01 2021 | - | -1.40 | - |
| Q04 2020 | - | -1.40 | - |
| Q03 2020 | - | -1.60 | - |
| Q02 2020 | - | -0.18 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -1.09 | 6.03 | Positive |
| 9/2022 QR | -1.06 | 4.50 | Positive |
| 12/2022 FY | -4.97 | -6.42 | Negative |
| 12/2023 FY | -3.61 | 14.66 | Positive |
| Next Report Date | 9th Aug 2022 |
| Estimated EPS Next Report | -1.09 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 63.03K |
| Shares Outstanding | 5.68K |
| Shares Float | 5.66M |
| Trades Count | 221 |
| Dollar Volume | 99.29K |
| Avg. Volume | 79.51K |
| Avg. Weekly Volume | 73.62K |
| Avg. Monthly Volume | 65.70K |
| Avg. Quarterly Volume | 99.20K |
Avinger Inc. (NASDAQ: AVGR) stock closed at 1.51 per share at the end of the most recent trading day (a -5.62% change compared to the prior day closing price) with a volume of 97.92K shares and market capitalization of 8.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 81 people. Avinger Inc. CEO is Jeffrey M. Soinski.
The one-year performance of Avinger Inc. stock is 32.46%, while year-to-date (YTD) performance is 235.56%. AVGR stock has a five-year performance of -99.14%. Its 52-week range is between 1.42 and 29.2, which gives AVGR stock a 52-week price range ratio of 0.47%
Avinger Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 0.89, a price-to-sale (PS) ratio of 0.91, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -75.29%, a ROC of -79.16% and a ROE of -181.77%. The company’s profit margin is -%, its EBITDA margin is -161.70%, and its revenue ttm is $9.46 Million , which makes it $1.67 revenue per share.
Of the last four earnings reports from Avinger Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. Avinger Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for Avinger Inc. is Strong Buy (1), with a target price of $7.5, which is +383.87% compared to the current price. The earnings rating for Avinger Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avinger Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avinger Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.58, ATR14 : 0.14, CCI20 : -48.95, Chaikin Money Flow : -0.48, MACD : -0.15, Money Flow Index : 50.10, ROC : -10.65, RSI : 37.99, STOCH (14,3) : 25.79, STOCH RSI : 0.64, UO : 26.65, Williams %R : -74.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avinger Inc. in the last 12-months were: Himanshu N. Patel (Option Excercise at a value of $0), James G. Cullen (Sold 216 shares of value $125 ), Jeffrey M. Soinski (Option Excercise at a value of $0), Mark B. Weinswig (Option Excercise at a value of $0), Mark Weinswig (Option Excercise at a value of $0)
Avinger Inc.
Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.
CEO: Jeffrey M. Soinski
Telephone: +1 650 241-7900
Address: 400 Chesapeake Drive, Redwood City 94063, CA, US
Number of employees: 81
TipRanks News for AVGR
Wed, 11 May 2022 11:45 GMT Analysts Offer Insights on Healthcare Companies: Avinger (AVGR) and Roche Holding AG (OtherRHHVF)
- TipRanks. All rights reserved.
